535 related articles for article (PubMed ID: 25054950)
21. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
Avis HJ; Hutten BA; Gagné C; Langslet G; McCrindle BW; Wiegman A; Hsia J; Kastelein JJ; Stein EA
J Am Coll Cardiol; 2010 Mar; 55(11):1121-6. PubMed ID: 20223367
[TBL] [Abstract][Full Text] [Related]
22. Lipid-lowering agents for nephrotic syndrome.
Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
[TBL] [Abstract][Full Text] [Related]
23. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
Aljenedil S; Ruel I; Watters K; Genest J
J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Statins in Children and Adolescents With Familial Hypercholesterolemia: A Systematic Review.
Dombalis S; Nash A
J Pediatr Health Care; 2021; 35(3):292-303. PubMed ID: 33342622
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
[TBL] [Abstract][Full Text] [Related]
26. The spectrum of statin therapy in hyperlipidemic children.
Rodenburg J; Vissers MN; Trip MD; Wiegman A; Bakker HD; Kastelein JJ
Semin Vasc Med; 2004 Nov; 4(4):313-20. PubMed ID: 15861313
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial.
Teramoto T; Kobayashi M; Tasaki H; Yagyu H; Higashikata T; Takagi Y; Uno K; Baccara-Dinet MT; Nohara A
Circ J; 2016 Aug; 80(9):1980-7. PubMed ID: 27452202
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
29. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.
Peretti N; Vimont A; Mas E; Lemale J; Reynaud R; Tounian P; Poinsot P; Restier L; Paillard F; Pradignac A; Pucheu Y; Rabès JP; Bruckert E; Gallo A; Béliard S
Arch Pediatr; 2024 Apr; 31(3):188-194. PubMed ID: 38538465
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening.
Kjærgaard KA; Christiansen MK; Schmidt M; Olsen MS; Jensen HK
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28652386
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin.
de Jongh S; Ose L; Szamosi T; Gagné C; Lambert M; Scott R; Perron P; Dobbelaere D; Saborio M; Tuohy MB; Stepanavage M; Sapre A; Gumbiner B; Mercuri M; van Trotsenburg AS; Bakker HD; Kastelein JJ;
Circulation; 2002 Oct; 106(17):2231-7. PubMed ID: 12390953
[TBL] [Abstract][Full Text] [Related]
32. Early initiation of statin treatment in children with familial hypercholesterolaemia.
Braamskamp MJ; Hutten BA; Wiegman A
Curr Opin Lipidol; 2015 Jun; 26(3):236-9. PubMed ID: 25943840
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability.
Carreau V; Girardet JP; Bruckert E
Paediatr Drugs; 2011 Aug; 13(4):267-75. PubMed ID: 21692550
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.
Stein EA; Dann EJ; Wiegman A; Skovby F; Gaudet D; Sokal E; Charng MJ; Mohamed M; Luirink I; Raichlen JS; Sundén M; Carlsson SC; Raal FJ; Kastelein JJP
J Am Coll Cardiol; 2017 Aug; 70(9):1162-1170. PubMed ID: 28838366
[TBL] [Abstract][Full Text] [Related]
35. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects.
O'Gorman CS; Higgins MF; O'Neill MB
Pediatr Cardiol; 2009 May; 30(4):482-9. PubMed ID: 19189168
[TBL] [Abstract][Full Text] [Related]
36. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
37. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
Miname MH; Bittencourt MS; Nasir K; Santos RD
Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
[TBL] [Abstract][Full Text] [Related]
38. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
39. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial.
Koeijvoets KC; Rodenburg J; Hutten BA; Wiegman A; Kastelein JJ; Sijbrands EJ
Circulation; 2005 Nov; 112(20):3168-73. PubMed ID: 16286607
[TBL] [Abstract][Full Text] [Related]
40. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
